Article
Association of morphological changes in Spectral Domain OCT and Visual acuity in Anti-VEGF-treatment of exudative AMD
Search Medline for
Authors
Published: | May 30, 2012 |
---|
Outline
Text
Background: Anti-VEGF-therapy is actually a main treatment of exudative AMD. However different treatment regimens (e.g. Recommendation DOG 2010) can be observed resulting in different response to the treatment. Therefore, we analysed visual acuity under various schemes in association to morphological changes in the spectral domain OCT for visual acuity.
Method: We collected data from 178 eyes under Ranibizumab therapy, including 120 eyes treated by an old treatment regimen (re-treatment in case of loss of visual acuity) and 58 eyes following the treatment recommendation since 2010. In addition to clinical examination of the best-corrected visual acuity (VA), angiography and spectral-domain OCT (Spectralis HRA III) have been conducted. We differentiated the presence of intra-and subretinal fluid or photoreceptor-layer- discontinuity.
Results: In mean an increase in visual acuity (rmANOVA p <0.01) could be measured in all groups, which was in the group with current treatment recommendations is a better visual outcome over a follow-up of > 1 year. A worse visual outcome was also detected for the presence of cystoid changes.
Conclusions: These results indicate the superiority of the new treatment regimen and an association between morphological findings on the integrity of the OCT retinal layers, and suggest as measures of treatment success and prognosis of exudative AMD.